Baker Hughes vs NOV
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Baker Hughes and NOV side by side, using each one’s latest annual report. Here is what stands out:
- Baker Hughes is the larger business, with $27.7B of revenue in fiscal 2025 against $8.7B for NOV, about 3.2 times as much.
- Baker Hughes grew revenue faster (−0.3%, against −1.4%).
- NOV turned more of its sales into free cash flow (10.0% FCF margin, against 9.2%).
- Baker Hughes earned a higher return on the capital invested in it (14.1%, against 3.5%).
Who comes out ahead
Of the 7 measures where higher (or lower) is clearly better, how many each company leads.
Baker Hughes
BKR
4/7
Revenue growthNet marginReturn on capitalReturn on equity
NOV
NOV
3/7
5-year growthFCF marginNet debt / EBITDA
Side by side
Best in the row
| Latest fiscal year | BKR FY25 | NOV FY25 |
|---|---|---|
| Size | ||
| Market cap | — | $7.3B |
| Revenue | $27.7B | $8.7B |
| Free cash flow | $2.5B | $876M |
| Net income | $2.6B | $145M |
| Growth | ||
| Revenue growth | −0.3% | −1.4% |
| 5-year growth | 6.0% | 7.5% |
| Share count change | — | −5.3% |
| Profitability | ||
| Gross margin | — | 20.2% |
| Operating margin | — | 5.7% |
| Net margin | 9.3% | 1.7% |
| FCF margin | 9.2% | 10.0% |
| Return on capital | 14.1% | 3.5% |
| Return on equity | 14.5% | 2.3% |
| Balance sheet | ||
| Net debt | $2.4B | $428M |
| Net debt / EBITDA | 0.5x | 0.5x |
| Dividends and buybacks | $1.3B | $505M |
| Valuation & quality | ||
| P/E | — | 80.8x |
| Piotroski F-score | — | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.